MedTrace Logo

Biomarkers of Renal Cancer

NCT05785052 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-03-27

No results posted yet for this study

Summary

The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe).

This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.

Conditions

Sponsors & Collaborators

  • Biorek S.R.L.

    lead INDUSTRY

Principal Investigators

  • Francesco Montorsi · IRCCS San Raffaele

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-11
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05785052 on ClinicalTrials.gov